Bioequivalence challenges in development of fixed-dose combination products : looking beyond reformulation
INTRODUCTION: Bioequivalence study is a critical step in the development of novel fixed-dose combination products (FDCPs). While bioequivalence of prototype FDCP to the approved monocomponent products facilitates speedier development and approval, lack of bioequivalence often leads to development de...
|Published in:||Expert opinion on drug delivery, Vol. 9, No. 3 (2012), p. 325-32|
|Item Description:||Date Completed 10.04.2013|
Date Revised 01.12.2018
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
|QR Code:||Show QR Code|